SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 354.89 Billion KRW | 44.16% |
| 2022 | 246.17 Billion KRW | -41.2% |
| 2021 | 418.64 Billion KRW | 1510.23% |
| 2020 | 25.99 Billion KRW | -79.01% |
| 2019 | 123.85 Billion KRW | 11172.24% |
| 2018 | 1.09 Billion KRW | -98.71% |
| 2017 | 85.31 Billion KRW | -5.13% |
| 2016 | 89.92 Billion KRW | 25.92% |
| 2015 | 71.41 Billion KRW | -1.41% |
| 2014 | 72.44 Billion KRW | 19.83% |
| 2013 | 60.45 Billion KRW | 16.71% |
| 2012 | 51.79 Billion KRW | 37.65% |
| 2011 | 37.63 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 133.99 Billion KRW | 17.57% |
| 2024 Q1 | 113.97 Billion KRW | -10.08% |
| 2023 Q1 | 60.78 Billion KRW | -3.16% |
| 2023 Q3 | 90.33 Billion KRW | 17.3% |
| 2023 Q2 | 77.01 Billion KRW | 26.7% |
| 2023 FY | 354.89 Billion KRW | 44.16% |
| 2023 Q4 | 126.75 Billion KRW | 40.31% |
| 2022 FY | 246.17 Billion KRW | -41.2% |
| 2022 Q4 | 62.76 Billion KRW | -29.34% |
| 2022 Q3 | 88.83 Billion KRW | 66.25% |
| 2022 Q2 | 53.43 Billion KRW | 29.87% |
| 2022 Q1 | 41.14 Billion KRW | -82.17% |
| 2021 FY | 418.64 Billion KRW | 1510.23% |
| 2021 Q4 | 230.73 Billion KRW | 863.38% |
| 2021 Q2 | 23.96 Billion KRW | -82.88% |
| 2021 Q3 | 23.95 Billion KRW | -0.08% |
| 2021 Q1 | 139.98 Billion KRW | 770.43% |
| 2020 FY | 25.99 Billion KRW | -79.01% |
| 2020 Q4 | 16.08 Billion KRW | 309.96% |
| 2020 Q2 | 2.06 Billion KRW | -47.42% |
| 2020 Q1 | 3.92 Billion KRW | 1873.03% |
| 2020 Q3 | 3.92 Billion KRW | 89.94% |
| 2019 Q4 | 199.07 Million KRW | 143.79% |
| 2019 FY | 123.85 Billion KRW | 11172.24% |
| 2019 Q3 | 81.65 Million KRW | -98.75% |
| 2019 Q2 | 6.5 Billion KRW | -94.44% |
| 2019 Q1 | 117.06 Billion KRW | 0.0% |
| 2018 FY | 1.09 Billion KRW | -98.71% |
| 2017 FY | 85.31 Billion KRW | -5.13% |
| 2016 FY | 89.92 Billion KRW | 25.92% |
| 2015 FY | 71.41 Billion KRW | -1.41% |
| 2014 FY | 72.44 Billion KRW | 19.83% |
| 2013 FY | 60.45 Billion KRW | 16.71% |
| 2012 FY | 51.79 Billion KRW | 37.65% |
| 2011 FY | 37.63 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ORIENT BIO Inc. | 28 Billion KRW | -1167.238% |
| Green Cross Holdings Corporation | 2057.93 Billion KRW | 82.755% |
| Green Cross Holdings Corporation | 1626.64 Billion KRW | 78.183% |
| Pharmicell Co., Ltd. | 56.22 Billion KRW | -531.172% |
| Green Cross Corporation | 1626.64 Billion KRW | 78.183% |
| GeneOne Life Science, Inc. | 40.2 Billion KRW | -782.751% |
| Celltrion, Inc. | 2176.43 Billion KRW | 83.694% |
| Samsung Biologics Co.,Ltd. | 3694.58 Billion KRW | 90.394% |
| SK bioscience Co.,Ltd. | 369.5 Billion KRW | 3.955% |
| Prestige BioPharma Limited | 689.07 Million KRW | -51402.602% |